{
    "clinical_study": {
        "@rank": "148005", 
        "arm_group": [
            {
                "arm_group_label": "dietary supplement with antioxidants", 
                "arm_group_type": "Experimental", 
                "description": "Dietary supplement with antioxidants, Ginkgo biloba, Bilberry extract"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Experimental", 
                "description": "Placebo identical in appearance to active"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective is to evaluate the effects of an antioxidant formula versus placebo on ocular\n      blood flow in a randomized double-blind, crossover design.\n\n      Based upon preliminary data, it is hypothesized that a dietary supplement containing a\n      variety of ingredients with antioxidant properties will, compared to placebo, increase\n      ocular perfusion pressure, retrobulbar, retinal capillary and choroidal blood flow, and\n      maintain these effects over the course of the treatment period."
        }, 
        "brief_title": "The Effects of an Antioxidant Formulation on Ocular Blood Flow", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Open Angle Glaucoma", 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 30 years or older.\n\n          -  Confirmed diagnosis of open angle glaucoma by glaucoma specialist in the study eye,\n             as evidenced from criteria representative of glaucomatous optic nerve damage such as\n             specific optic disc or retinal nerve fiber layer structural abnormalities and/or\n             visual field abnormalities.\n\n          -  Best corrected visual acuity at 20/60 or better in study eye.\n\n          -  Willingness to avoid caffeine and smoking for 12 hours before and during the study\n             visits.\n\n        Exclusion Criteria:\n\n          -  History of acute angle-closure or a narrow, occluding of anterior chamber angle by\n             gonioscopy.\n\n          -  History of chronic or recurrent inflammatory eye diseases or signs of intraocular\n             trauma and/or unreliable applanation tonometry.\n\n          -  Severe, unstable or uncontrolled cardiovascular, renal or pulmonary disease\n\n          -  History of/or current renal or hepatic impairment.\n\n          -  History of/or current bronchial asthma, severe chronic obstructive pulmonary disease,\n             sinus bradycardia, second or third degree atrioventricular block, or cardiogenic\n             shock.\n\n          -  Recent surgery or surgery planned near study timeline\n\n          -  History of bleeding disorder\n\n          -  Use of blood thinning medications\n\n          -  Use of specified dietary supplements for three weeks prior to study entry and\n             throughout study period."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930487", 
            "org_study_id": "007"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "dietary supplement with antioxidants", 
                    "placebo"
                ], 
                "description": "Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids", 
                "intervention_name": "dietary supplement with antioxidants", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Optic Nerve Formula"
            }, 
            {
                "arm_group_label": [
                    "dietary supplement with antioxidants", 
                    "placebo"
                ], 
                "description": "Placebo\nSoftgels manufactured to mimic the appearance of active, dietary supplement with antioxidants", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antioxidants"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Primary open angle glaucoma", 
            "intraocular pressure", 
            "ocular perfusion pressure", 
            "retrobulbar blood flow", 
            "retinal capillary blood flow", 
            "choroidal blood flow"
        ], 
        "lastchanged_date": "October 23, 2013", 
        "location": {
            "contact": {
                "email": "bsiesky@indiana.edu", 
                "last_name": "Brent A Siesky, PhD", 
                "phone": "317-278-0177"
            }, 
            "facility": {
                "address": {
                    "city": "Indianapolis", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "46202"
                }, 
                "name": "Glick Eye Institute, Ocular Vascular Research Center, Indiana University School of Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effects of an Antioxidant Formulation on Intraocular Pressure, Ocular Perfusion Pressure, Retrobulbar, Retinal Capillary and Choroidal Blood Flow", 
        "overall_contact": {
            "email": "bsiesky@indiana.edu", 
            "last_name": "Brent A. Siesky, PhD", 
            "phone": "317-278-0177"
        }, 
        "overall_contact_backup": {
            "email": "alharris@indiana.edu", 
            "last_name": "Alon Harris, PhD", 
            "phone": "317-278-0177"
        }, 
        "overall_official": {
            "affiliation": "Professor of Ophthalmology, Professor of Cellular and Integrative Physiology, Director Clinical Research Glick Eye Institute, Indiana University Medical Center", 
            "last_name": "Alon Harris, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "retinal capillary blood flow in arbitrary units.", 
                "measure": "retinal capillary blood flow", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Central retinal artery, ophthalmic artery, and temporal and nasal short posterior artery:  peak systolic and end diastolic blood flow velocities (cm/s) and vascular resistance (ratio).", 
                "measure": "Retrobulbar blood flow velocities and vascular resistance", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930487"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "2/3 Mean arterial pressure - intraocular pressure", 
                "measure": "Ocular perfusion pressure", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "description": "an measure used to estimate choroid blood flow in bulk", 
                "measure": "Ocular pulse amplitude", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }
        ], 
        "source": "ScienceBased Health", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ScienceBased Health", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}